This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Isracann Biosciences Yönetim

Yönetim kriter kontrolleri 0/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Ajay Kaila

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

CEO

Ajay Kaila

1.5yrs

Görev süresi

Ajay Singh Kaila is Interim Chief Executive Officer of Isracann Biosciences Inc. from January 20, 2023.

This company listing is no longer active

Isracann Biosciences Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Isracann Biosciences Inc. Announces Management Changes

Isracann Biosciences Inc., Annual General Meeting, Mar 31, 2023

Isracann Biosciences Inc. Appoints Ajay Singh Kaila as Interim CEO

Isracann Biosciences Inc. Announces Resignation of James Thompson as Chief Operations Officer

Less than half of directors are independent

Isracann Biosciences Inc. Announces the Resignation of Irit Arbel as Director

Recent updates

Isracann Biosciences Inc. Announces Management Changes

New minor risk - Financial data availability

Isracann Biosciences Inc. announced that it has received CAD 0.025 million in funding

Isracann Biosciences Inc., Annual General Meeting, Mar 31, 2023

Isracann Biosciences Inc. Appoints Ajay Singh Kaila as Interim CEO

Isracann Biosciences Inc. Announces Resignation of James Thompson as Chief Operations Officer

Less than half of directors are independent

Isracann Biosciences Inc. Announces the Resignation of Irit Arbel as Director

Isracann Biosciences Inc., Annual General Meeting, Nov 16, 2022

Isracann Biosciences Inc. Appoints Mark Rypien to Its Advisory Board

Isracann Biosciences Inc. Announces Executive Changes

Isracann Biosciences Inc. Announces Executive Changes

Isracann Biosciences Inc. Appoints George Vrabec to the Position of Director of Natural Health Products

Isracann Biosciences Inc. (CNSX:IPOT) entered into a binding Letter of Intent to acquire Praesidio Health Inc. for CAD 4 million.

Isracann Biosciences Inc. (CNSX:IPOT) entered into a binding LOI to acquire Praesidio Health Inc. for CAD 4 million.

New 90-day high: CA$0.33

New 90-day high: CA$0.28

Isracann Biosciences Inc. Auditor Raises 'Going Concern' Doubt

An unknown buyer entered into an agreement to acquire Net Assets of Atlas Cloud Enterprises (2013) Ltd. from Isracann Biosciences Inc. (CNSX:IPOT) for CAD 0.28 million.

Isracann Biosciences Inc. (CNSX:IPOT) completed the acquisition of 50% stake in Cannation Ltd. from Intelicanna Ltd (TASE:INTL).

New 90-day low: CA$0.24

New 90-day low - CA$0.26

CEO

Görev süresi